This impressive FTSE small-cap is on my list of ones to watch. Here’s what I’d do now

Jabran Khan delves deeper into a FTSE small cap he believes will begin to soar in the future and why he thinks it may be worth buying cheaply right now.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I like to think of myself as a savvy investor. And for me, part of building a diverse portfolio involves looking for the next big thing on the FTSE AIM index.

Yourgene Health Plc (LSE:YGEN) is on my ‘ones to watch list’ list. It’s a genetic testing firm that produces non-invasive products for male fertility and prenatal screening for cystic fibrosis and other genetic disorders. In addition, YGEN is planning to expand into genetic testing for cancer detection and prevention. YGEN has also joined the Covid-19-related products market with its own testing solution.

FTSE AIM opportunity

YGEN has been listed on the FTSE AIM for six years and has been steadily increasing its footprint. It has established a commercial presence in the UK, Europe, the Middle East, Africa and Asia.

YGEN does relies on commercial partnerships with bigger DNA testing firms out there but I do not see this as a drawback. Sometimes smaller companies will bring fresh ideas and proprietary knowledge to the table. Larger firms then utilise their own infrastructure and reach and both parties benefit.

I always take notice of companies who undergo acquisitions to grow, especially into new territories such as the US. Yourgene acquired Elucigene in April 2019 and launched its first oncology product. I believe this is a statement of ambition and will help it to reach new heights.

As I write this, shares in YGEN can be picked up for a very modest 17p per share. Just before the market crash that rocked the whole FTSE index, shares were trading very close to a similar level of 17p. The crash did cause a small dip in price and shares could be purchased at just 10p. Even at current prices, I consider this a bargain with very little risk involved.

Recent performance

On Monday, YGEN released a half-year trading update for the six months ending 30 September 2020. There were several positive takeaways from this report. Revenue increased 5% compared to the same period last year. The UK and Europe each saw a healthy increase of 40% and 80% respectively. This helped offset a reduction in revenue for the rest of the world. This was to be expected as many firms across the FTSE reported difficulties due to the market crash. YGEN also saw revenues for its Covid-19 testing solution begin to increase and the forecast for the second half of the year is positive.

In addition to the financials, YGEN raised £15m of funds to complete a new acquisition in the form of Canadian firm Coastal Genomics, which I believe will further its reach in the North American market.

My verdict

I really like the look of Yourgene even though it is just a £128m market cap business. It is making good headway with its footprint and is attempting to gain a share of a multi-billion pound industry. It is regularly acquiring smaller firms and amalgamating them into its operation to enhance its offering. Also, YGEN is showing growth in respect of revenue and has joined the potentially lucrative Covid-19 product market.

At its current price, I believe YGEN represents a bargain, albeit with a small amount of risk involved. I like picking up FTSE small-caps when they have potential such as this, as it helps diversify my portfolio.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Jabran Khan has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

Is the S&P 500 going to 10,000 by 2030? This expert thinks so

One stock market strategist sees animal spirits taking hold and driving the S&P 500 index even higher by the end…

Read more »